AT248835T - Prodrugs of impdh inhibiting carbamates - Google Patents

Prodrugs of impdh inhibiting carbamates

Info

Publication number
AT248835T
AT248835T AT00950246T AT00950246T AT248835T AT 248835 T AT248835 T AT 248835T AT 00950246 T AT00950246 T AT 00950246T AT 00950246 T AT00950246 T AT 00950246T AT 248835 T AT248835 T AT 248835T
Authority
AT
Austria
Prior art keywords
carbamates
prodrugs
impdh
inhibiting
impdh inhibiting
Prior art date
Application number
AT00950246T
Other languages
German (de)
Inventor
Dean P Stamos
Randy S Bethiel
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14110299P priority Critical
Application filed by Vertex Pharma filed Critical Vertex Pharma
Priority to PCT/US2000/017400 priority patent/WO2001000622A1/en
Publication of AT248835T publication Critical patent/AT248835T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
AT00950246T 1999-06-25 2000-06-23 Prodrugs of impdh inhibiting carbamates AT248835T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14110299P true 1999-06-25 1999-06-25
PCT/US2000/017400 WO2001000622A1 (en) 1999-06-25 2000-06-23 Prodrugs of carbamate inhibitors of impdh

Publications (1)

Publication Number Publication Date
AT248835T true AT248835T (en) 2003-09-15

Family

ID=22494164

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950246T AT248835T (en) 1999-06-25 2000-06-23 Prodrugs of impdh inhibiting carbamates

Country Status (12)

Country Link
US (4) US6395763B1 (en)
EP (1) EP1196414B1 (en)
JP (1) JP4773010B2 (en)
AT (1) AT248835T (en)
AU (1) AU780973B2 (en)
CA (1) CA2377278C (en)
DE (1) DE60005017T2 (en)
DK (1) DK1196414T3 (en)
ES (1) ES2200902T3 (en)
MX (1) MXPA02000294A (en)
PT (1) PT1196414E (en)
WO (1) WO2001000622A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0009167A (en) * 1999-03-19 2001-12-26 Vertex Pharma Impdh enzyme inhibitors
MXPA02000294A (en) 1999-06-25 2002-06-21 Vertex Pharma Prodrugs of carbamate inhibitors of impdh.
KR20020067545A (en) * 1999-12-16 2002-08-22 테바 파마슈티컬 인더스트리즈 리미티드 Novel processes for making- and a new crystalline form of- leflunomide
AT526339T (en) 2001-01-22 2011-10-15 Merck Sharp & Dohme Nucleoside derivatives as inhibitors of the rna-dependent viral rna polymerase
AU2003261354A1 (en) * 2002-08-02 2004-02-23 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
SG182849A1 (en) * 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2004096287A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
CN101410120A (en) * 2003-04-25 2009-04-15 吉里德科学公司 Anti-inflammatory phosphonate compounds
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US20070281907A1 (en) * 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
KR20060022647A (en) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 Kinase inhibitory phosphonate analogs
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
DE602004019815D1 (en) * 2003-12-22 2009-04-16 Gilead Sciences Inc 4'-substituted carbovir and abacavir derivatives and related compounds with hiv and hcv antiviral effect
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
JP5055564B2 (en) 2004-06-15 2012-10-24 アイシス ファーマシューティカルズ, インコーポレーテッド C-purine nucleoside analogues as inhibitors of RNA-dependent RNA viral polymerase
WO2006012078A2 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
PL216369B1 (en) 2004-07-27 2014-03-31 Gilead Sciences, Inc. Phosphonium analogs of HIV inhibitors
JP2008518024A (en) * 2004-10-26 2008-05-29 ギリアード サイエンシーズ, インコーポレイテッド Phosphonate derivatives of mycophenolic acid
JP4705164B2 (en) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション HCV NS3 protease inhibitor
TWI387603B (en) 2005-07-20 2013-03-01 Merck Sharp & Dohme Hcv ns3 protease inhibitors
RU2008107972A (en) 2005-08-01 2009-09-10 Мерк энд Ко., Инк. (US) Macrocyclic peptides as hcv ns3-protease inhibitors
DE102006007146A1 (en) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl prodrugs
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
DE102006039589A1 (en) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl prodrugs II
AU2007309544B2 (en) 2006-10-24 2012-05-31 Msd Italia S.R.L. HCV NS3 protease inhibitors
CN101583372A (en) 2006-10-24 2009-11-18 默克公司 HCV NS3 protease inhibitors
EP2076278B1 (en) 2006-10-24 2015-05-06 Merck Sharp & Dohme Corp. Macrocyclic HCV NS3 protease inhibitors
CN101568346B (en) 2006-10-27 2015-11-25 默沙东公司 HCV NS3 protease inhibitor
EP2086982B1 (en) 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2121707B1 (en) 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Antiviral indoles
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
DE102007032344A1 (en) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Prodrug derivatives of 1- (4-methoxyphenyl) -7-oxo-6- [4- (2-oxopiperidin-1-yl) phenyl] -4,5,6,7-tetrahydro-1H-pyrazolo [3,4 -c] pyridine-3-carboxamide
DE102007032345A1 (en) 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl prodrugs
DE102007032347A1 (en) 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl prodrugs
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
WO2009010804A1 (en) 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
GB0718575D0 (en) 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
WO2009100135A2 (en) * 2008-02-04 2009-08-13 Medical College Georgia Research Institute, Inc. Hla-g compositions and methods of use thereof
CN102014911A (en) 2008-04-28 2011-04-13 默沙东公司 HCV NS3 protease inhibitors
NZ590075A (en) 2008-07-08 2012-12-21 Gilead Sciences Inc citrate, malonate and succinate salts of the HIV inhibitor ethyl N-[(S)({ [(2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy} methyl)phenoxyphosphinoyl]-L-alaninate
SI2310095T1 (en) 2008-07-22 2013-01-31 Merck Sharp & Dohme Corp. Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
WO2013106344A1 (en) 2012-01-12 2013-07-18 Ligand Pharmaceuticals, Inc. 2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
WO2014043380A1 (en) 2012-09-14 2014-03-20 Ligand Pharmaceuticals Incorporated Novel nucleotide prodrug compounds and use
WO2015077368A1 (en) 2013-11-22 2015-05-28 Ligand Pharmaceuticals Incorporated Derivatives of uridine 5'-cyclophosphate useful to treat hepatitis c viral infections
CA2937548A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (en) 2014-07-02 2017-05-17 配体药物公司 Prodrug compounds and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1332306A (en) * 1969-12-23 1973-10-03 Glaxo Lab Ltd Antibiotics
DE2928485A1 (en) 1979-07-14 1981-01-29 Bayer Ag Use of urea derivatives as a drug for the treatment of dyslipidemia
US4892873A (en) * 1985-10-31 1990-01-09 American Cyanamid Company N-substituted -N-(3-(1,2,4-triazolo-(4,3-b)pyridazin-6-yl)phenyl)alkanamides, carbamates and ureas
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
IT1226727B (en) * 1988-07-29 1991-02-05 Simes Drugs dopamine precursors.
FR2644462B1 (en) * 1988-09-23 1993-07-09 Ire Celltarg Sa New compounds active against tissue forms of malaria and method of preparing
US4942226A (en) 1988-12-29 1990-07-17 Merck & Co., Inc. Halogenated pyrimidine nucleosides and their derivatives
US5495047A (en) 1991-07-10 1996-02-27 Merck, Sharp & Dohme (Ltd.) Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
US5534632A (en) 1991-09-05 1996-07-09 Abbott Laboratories Macrocyclic carbamate immunomodulators
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994012184A1 (en) 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5380879A (en) 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US5444072A (en) 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US5576313A (en) 1994-08-29 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
IL126674A (en) * 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
MXPA02000294A (en) 1999-06-25 2002-06-21 Vertex Pharma Prodrugs of carbamate inhibitors of impdh.

Also Published As

Publication number Publication date
DK1196414T3 (en) 2003-11-24
JP2003503408A (en) 2003-01-28
US7777069B2 (en) 2010-08-17
AU780973B2 (en) 2005-04-28
PT1196414E (en) 2003-12-31
AU6337400A (en) 2001-01-31
JP4773010B2 (en) 2011-09-14
ES2200902T3 (en) 2004-03-16
CA2377278C (en) 2010-03-23
US20050101664A1 (en) 2005-05-12
EP1196414B1 (en) 2003-09-03
MXPA02000294A (en) 2002-06-21
US6395763B1 (en) 2002-05-28
DE60005017T2 (en) 2004-06-09
CA2377278A1 (en) 2001-01-04
EP1196414A1 (en) 2002-04-17
US20090093639A1 (en) 2009-04-09
WO2001000622A1 (en) 2001-01-04
DE60005017D1 (en) 2003-10-09
US20020161038A1 (en) 2002-10-31
US6825224B2 (en) 2004-11-30

Similar Documents

Publication Publication Date Title
DE60030619D1 (en) guard
DE60008133D1 (en) Dye-marked imidazochinoline compounds
DE69917811D1 (en) Photostable sun protectors
DK1818396T3 (en) Alpha-amylase variants
DE60017831D1 (en) Derivative compositions
DE69816280D1 (en) Inhibitors of the impdh enzyme
DE60020716D1 (en) Film-constructed compositions from pullulan
DK1156798T3 (en) Felbamate-derived compounds
DE60006541D1 (en) Src-kinase inhibiting compounds
DE50015137D1 (en) Device for the protected operation of neuroprotheses
DE60001229D1 (en) triarylimidazoles
DE60110621D1 (en) Mounting of inflatable elements
DE50013492D1 (en) Optical arrangement
DE60017787D1 (en) Radiation-sensitive liposomes
DE60002193D1 (en) Metaloprotease inhibitors
DK1187933T3 (en) Betalactam-containing compounds
DE60038793D1 (en) For field effects
DE60018203D1 (en) Cis-jasmon as semio-chemical
DE60021581D1 (en) Lance tes compilation
DE50015853D1 (en) Process for protection of data
DK1237408T3 (en) Pour-on formulations
DE60006380D1 (en) Band aid
DK1206182T3 (en) herbicidal compositions
DE60021276D1 (en) Mask
FR2800580B1 (en) Protective helmet

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1196414

Country of ref document: EP